UBS Group
ALLR

UBS Group’s Allarity Therapeutics ALLR Stock Holding History

UBS Group’s Portfolio ALLR Stock Details ALLR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25.2K Sell
23,158
-3,358
-13% -$3.61K ﹤0.01% 7785
2025
Q4 		$28.6K Buy
+26,516
New +$33.8K ﹤0.01% 7555
2025
Q3 		– Sell
-47,984
Closed -$48.5K – 10300
2025
Q2 		$48.5K Buy
47,984
+47,684
+15,895% +$45.1K ﹤0.01% 7803
2025
Q1 		$281 Buy
+300
New +$310 ﹤0.01% 9851
2024
Q4 		– Sell
-18,452
Closed -$38.9K – 9886
2024
Q3 		$38.9K Buy
18,452
+17,078
+1,243% +$80.2K ﹤0.01% 6980
2024
Q2 		$8.78K Buy
1,374
+1,319
+2,398% +$51.8K ﹤0.01% 7779
2024
Q1 		$9.94K Buy
+55
New +$13.8K ﹤0.01% 7257
2023
Q3 		– Sell
-6
Closed -$23.9K – 9415
2023
Q2 		$23.9K Buy
+6
New +$71.3K ﹤0.01% 6803
2023
Q1 		– Hold
0
– – – 9509
2022
Q4 		– Hold
0
– – – 10582
2022
Q3 		– Hold
0
– – – 7778
2022
Q2 		– Hold
0
– – – 9274
2022
Q1 		– Hold
0
– – – 8528
2021
Q4 		– Hold
0
– – – 9945

Other funds holding ALLR

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

UBS Group's ALLR Position: Q1 2026 in Review

UBS Group reduced its Allarity Therapeutics (ALLR) stake by 13% in Q1 2026, selling an estimated $3.61K and leaving 23,158 shares worth $25.2K. The position accounts for ﹤0.01% of the portfolio, ranked #7785.

UBS Group first reported a position in ALLR in Q2 2023 and has held it in 8 quarters since. The position peaked at $48.5K in Q2 2025. 14 funds tracked by Wall St. Rank hold ALLR as of Q1 2026.

  • UBS Group held 23,158 shares of Allarity Therapeutics worth $25.2K as of Q1 2026.
  • UBS Group sold 3,358 Allarity Therapeutics shares in Q1 2026, an estimated $3.61K.
  • Allarity Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #7785 holding.
  • UBS Group first reported a position in Allarity Therapeutics in Q2 2023 and has held it in 8 quarters since.
  • UBS Group's Allarity Therapeutics position peaked at $48.5K in Q2 2025.
  • 14 funds tracked by Wall St. Rank held Allarity Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.